• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcellx, Inc. - Common Stock (NQ: ACLX )

    79.02 +1.44 (+1.86%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 279,811
    Open 77.05
    Bid (Size) 31.52 (2)
    Ask (Size) 80.00 (1)
    Prev. Close 77.58
    Today's Range 76.67 - 79.50
    52wk Range 47.88 - 107.37
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    In-Depth Examination Of 14 Analyst Recommendations For Arcellx
    Via Benzinga
    Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
    The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
    Via Investor's Business Daily

    Performance

    YTD
    +40.73%
    +40.73%
    1 Month
    -13.13%
    -13.13%
    3 Month
    -6.09%
    -6.09%
    6 Month
    +46.01%
    +46.01%
    1 Year
    +37.21%
    +37.21%

    More News

    Read More
    14 Analysts Have This To Say About Arcellx
    Via Benzinga
    Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
    Via Benzinga
    Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
    From Arcellx, Inc.
    Via Business Wire
    Analyst Expectations For Arcellx's Future
    Via Benzinga
    Navigating 7 Analyst Ratings For Arcellx
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Arcellx
    Via Benzinga
    Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
    From Arcellx, Inc.
    Via Business Wire
    Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
    From Arcellx, Inc.
    Via Business Wire
    4 Analysts Assess Arcellx: What You Need To Know
    Via Benzinga
    Assessing Arcellx: Insights From 7 Financial Analysts
    Via Benzinga
    Decoding 8 Analyst Evaluations For Arcellx
    Via Benzinga
    ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
    From Arcellx, Inc.
    Via Business Wire
    FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
    Via InvestorPlace
    Exposures Product Safety
    Arcellx Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    The Latest Analyst Ratings For Arcellx
    Via Benzinga
    Expert Ratings For Arcellx
    Via Benzinga
    Analyst Expectations For Arcellx's Future
    Via Benzinga
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Via InvestorPlace
    ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    From Arcellx, Inc.
    Via Business Wire
    Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    From Gilead Sciences, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.